Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in Net LoansChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Cash from Investing Activities (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Cash from Investing Activities for 10 consecutive years, with -$29654.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities changed N/A year-over-year to -$29654.0, compared with a TTM value of -$344013.0 through Dec 2025, changed N/A, and an annual FY2025 reading of -$1.2 million, changed N/A over the prior year.
  • Cash from Investing Activities was -$29654.0 for Q4 2025 at Abvc Biopharma, up from -$513357.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $426846.0 in Q4 2021 and bottomed at -$1.5 million in Q3 2022.
  • Average Cash from Investing Activities over 5 years is -$226572.8, with a median of -$83288.0 recorded in 2022.
  • The sharpest move saw Cash from Investing Activities soared 298.52% in 2021, then tumbled 1245.25% in 2025.
  • Year by year, Cash from Investing Activities stood at $426846.0 in 2021, then tumbled by 119.51% to -$83288.0 in 2022, then skyrocketed by 285.11% to $154173.0 in 2023, then crashed by 70.93% to $44825.0 in 2024, then tumbled by 166.16% to -$29654.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for ABVC at -$29654.0 in Q4 2025, -$513357.0 in Q3 2025, and $44825.0 in Q3 2024.